Alphabet’s biolab in funding talks at $40B valuation

The company hopes the new investment will accelerate its push to develop new drugs. Alphabet’s Isomorphic Labs is reportedly in fundraising talks at a $40 billion valuation, the latest sign of strong investor appetite for AI despite growing fears of a bubble. The company — led by Nobel Prize winner and former Google DeepMind CEO Demis Hassabis — hopes the new investment will accelerate its push to develop new drugs. Firms including China’s DeepSeek and Moonshot, as well as industry giant OpenAI, are also chasing billions in fresh funding as they look to stay ahead in the global AI race. However, experts fear that the vast amount of spending on AI, which is on track to far exceed past investment booms, is creating a bubble that, were it to burst, would lead to “ a far-reaching shock. ”